ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers.
Quiver AI Summary
ProPhase Labs Inc. announced the successful validation of its BE-Smart™ molecular diagnostic test for diagnosing esophageal diseases, achieving a technical success rate of over 95% using esophageal brush cytology samples. This advancement is significant for the estimated 60 million Americans affected by conditions like Barrett's esophagus and esophageal adenocarcinoma (EAC), which has high mortality rates. The BE-Smart test, which uses a proprietary biomarker panel, enhances the detection of cancer cells and will soon be commercially launched as a laboratory developed test, targeting a market valued at around $10 billion. Unlike traditional forceps biopsies, BE-Smart can analyze both brush and forceps samples, addressing the challenges of missed diagnoses with current methods. The growing use of brush biopsies reflects a shift in esophageal diagnostics toward improved safety and diagnostic yield, especially as clinical evidence supports their efficacy. ProPhase Labs aims to improve cancer risk stratification and disease monitoring with BE-Smart, contributing to better outcomes for patients with esophageal disorders.
Potential Positives
- BE-Smart has achieved over a 95% success rate in detecting biomarkers related to esophageal diseases, validating its effectiveness and reliability.
- The test's dual capability to analyze both forceps and brush biopsies positions it uniquely in the market, addressing the limitations of traditional diagnostics and enhancing its appeal to clinicians.
- ProPhase Labs is moving towards the accelerated commercialization of BE-Smart, with a clinical launch expected within 2-3 quarters, indicating strong market readiness.
- With a target market estimated at $10 billion, BE-Smart presents substantial revenue potential for ProPhase, significantly contributing to the company's growth strategy.
Potential Negatives
- Potential regulatory hurdles for the BE-Smart product may delay commercialization despite the reported success rate.
- The press release contains forward-looking statements that could mislead investors about the certainty of future revenues and operational success.
- Failure to meet commercialization timelines could negatively impact the company's credibility and stock performance.
FAQ
What is the BE-Smart™ test for esophageal disease?
BE-Smart™ is a molecular diagnostic test that detects biomarkers related to the progression of Barrett’s esophagus and esophageal cancer.
What success rate was achieved in the BE-Smart validation study?
The BE-Smart™ study demonstrated a greater than 95% technical success rate for detecting biomarkers in esophageal brush cytology samples.
How does BE-Smart improve esophageal cancer detection?
BE-Smart uses a proprietary panel of biomarkers that enhances the detection of cancer cells, particularly in esophageal adenocarcinoma cases.
When will BE-Smart be commercially launched?
The target clinical launch for BE-Smart™ is expected in the next 2-3 quarters, following successful validation.
What advantages do brush biopsies have in diagnosing esophageal diseases?
Brush biopsies allow for a wider sample collection and have a better diagnostic yield compared to traditional forceps biopsies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRPH Hedge Fund Activity
We have seen 19 institutional investors add shares of $PRPH stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WEXFORD CAPITAL LP added 1,525,611 shares (+inf%) to their portfolio in Q1 2025, for an estimated $616,804
- FOURWORLD CAPITAL MANAGEMENT LLC added 376,577 shares (+inf%) to their portfolio in Q1 2025, for an estimated $152,250
- QUINN OPPORTUNITY PARTNERS LLC added 318,127 shares (+inf%) to their portfolio in Q1 2025, for an estimated $128,618
- CITIZENS FINANCIAL GROUP INC/RI added 270,400 shares (+inf%) to their portfolio in Q1 2025, for an estimated $109,322
- JOSH ARNOLD INVESTMENT CONSULTANT, LLC added 250,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $101,075
- VANGUARD GROUP INC removed 246,765 shares (-37.7%) from their portfolio in Q1 2025, for an estimated $99,767
- WARBERG ASSET MANAGEMENT LLC removed 101,672 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $41,105
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States
Study shows >95% success rate, validating BE-Smart for use with esophageal brush cytology.
UNIONDALE, NY, June 17, 2025 (GLOBE NEWSWIRE) --
ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study evaluating the performance of the BE-Smart
™
molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart
™
achieved greater than a 95% technical success rate, confirming the BE-Smart’s ability to reliably and accurately detect our panel of biomarkers, designed to assess progression risk in Barrett’s esophagus and other distal esophageal conditions. Prophase will now move to accelerated commercialization of BE-Smart
™
with expected clinical launch in the next 2-3 quarters.
BE-Smart uses a proprietary panel of biomarkers and a multi-modal analysis method which together significantly increase detection of deadly cancer cells in one of the fastest growing cancer indications, esophageal denocarcinoma cancer or “EAC”. EAC has a 5-year mortality rate of over 79% and surged in annual incidence over 750% since the 1970s. BE-Smart represents a technical advance in detection and prognosis which has the potential to change cost and outcomes for the large population affected by GERD, Barrett’s and EAC globally.
“The ability to run BE-Smart on brush biopsy samples opens the door to much broader clinical use,” said Ted Karkus, CEO at ProPhase Labs. “Many leading molecular diagnostics cannot be used with brush biopsies. BE-Smart now stands apart as the only advanced molecular test designed to work with both forceps biopsies and brush-based tissue collection. We are now working toward commercialization as a laboratory developed test (LDT) with a target market of roughly $10 billion dollars, representing an exciting future for our Company.”
The dual capability of BE-Smart now validated to analyze both “pinch” and “brush” standard of care biopsies enables a powerful tool for comprehensive esophageal disease surveillance and clinical management. Pinch biopsies enable detailed analysis of specific areas, while brush biopsies gather a wider sample of epithelial cells, improving detection of disease across broader regions. Importantly, BE-Smart is commercially and clinically compatible with both of these broadly used approaches making it a dynamic and one-of-a-kind test.
Brush biopsies are rapidly emerging into mainstream clinical practice due to decreased cost and possibility of health complications associated with forceps biopsies. U.S. endoscopists perform approximately 6-7 million upper endoscopies (EGDs) each year, the majority of which still rely on traditional forceps biopsies alone. However, forceps sampling can miss up to 50% of focal areas of Barrett’s esophagus, particularly when the disease is patchy or limited to the squamous epithelium.
This shift toward brush biopsies is driven by their improved diagnostic yield and safety profile, addressing some of the limitations of traditional forceps biopsies. As clinical evidence mounts, these non-invasive techniques are gaining traction in both the U.S. and abroad, transforming the landscape of esophageal diagnostics. With expanded payer coverage now reaching over 73 million U.S. lives, and inclusion in leading gastroenterology guidelines, brush biopsies are increasingly recognized for their ability to capture a broader, more representative cell population compared to forceps alone.
Brush biopsies continue to grow in popularity among gastroenterologists and endoscopists, particularly for patients with GERD, Barrett’s esophagus, and other distal esophageal disorders. BE-Smart has been designed as the ideal molecular add-on testing platform for improving cancer risk stratification and disease monitoring. Improved measurement ability addresses the critical unmet need of early detection, treatment and improved outcomes.
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value.
www.ProPhaseLabs.com
Forward-Looking Statements
Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.
The information contained in this press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The statements made herein reflect the Company’s current views with respect to potential business opportunities and are based on currently available information, assumptions, and expectations. These statements are not guarantees of future performance or outcomes and are subject to risks and uncertainties. Comparisons to other companies or transactions, such as the referenced sale of 23andMe to Regeneron, are provided solely for illustrative purposes and do not imply any specific valuation or outcome for Nebula or any potential transaction involving it. No assurance can be given that any transaction will be pursued or consummated.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman:
jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
